

Señores

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO
DIVISION DE NUEVAS CREACIONES

E.

S.

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO



No. 05-096777- -00003-0000

Fecha: 2007-07-19 09:23:00 Dep. 2020 NUECREACIONE
Tra. 11 PATENTEIYII Eve: 379 FASENACIONALII
Act. 538 PETICION Folios: 2

Ref: Expediente No. 05-096.777

Solicitud de patente de invención titulada: "1,2,4-SUSTITUYENTE 1,2,3,4-TETRAHIDRO Y 1,2- DIHIDROQUINOLINA Y DERIVADOS E 1,2,3,4-TETRAHIDROQUINOXALINA COMO INHIBIDORES CETP PARA EL TRATAMIENTO DE ATEROSCLEROSIS Y ABESIDAD".

Solicitante: PFIZER PRODUCTS INC.

SOLICITUD DE EXAMEN DE PATENTABILIDAD SEGÚN
EL ARTÍCULO 44 DE LA DECISION 486, GACETA No. 577

CARLOS R. OLARTE, mayor de edad y vecino de Bogotá, D.C., identificado tal como aparece al pie de mi firma, en mi condición de apoderado del solicitante, respetuosamente me permito solicitar que se examine si la invención reúne los requisitos de patentabilidad previstos en la misma, dando cumplimiento a lo establecido en el artículo 44 de la Decisión 486 de la comisión de la Comunidad Andina de Naciones. Adjunto recibo por el monto de \$202.000 pesos para cubrir la tasa correspondiente, según la Resolución 36155 del año 2006.

Atentamente,

CARLOS R. OLARTE
C.C. 79.782.747 de Bogotá
T.P. 74.295

Anexo: Recibo por \$202.000 pesos

LMB/P2005/000133 070718

DIVISIÓN DE NUEVAS CREACIONES

RADICACIÓN EXPEDIENTE No. 05-96777

EL EXTRACTO DE LA PRESENTE SOLICITUD DE PATENTE DE INVENCION

FUE PUBLICADO EN LA GACETA DE PROPIEDAD INDUSTRIAL No 577 DE

FECHA 29 DE JUNIO DE 2007 EL TÉRMINO HÁBIL SEÑALADO POR LA LEY

EXPIRA EL 27 DE SEPTIEMBRE DE 2007

NOTA: Dentro del plazo de los seis (6) meses siguientes a partir de la fecha de publicación en la gaceta de Propiedad Industrial, deberá solicitar y cancelar el examen de patentabilidad so pena de que la solicitud caiga en abandono, de acuerdo con lo establecido en el Artículo 44 de la Decisión 486/2000.

SE PRESENTARON OPOSICIONES POR PARTE DE TERCEROS.

SI _____

NO _____ **X** _____

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 215/06, A61K 31/47, C07D 417/04, 413/04, 401/04, 221/18, 493/04, 471/04		A2	(11) International Publication Number: WO 96/19458
			(43) International Publication Date: 27 June 1996 (27.06.96)
(21) International Application Number: PCT/US95/16096		(72) Inventors: JONES, Todd, K.; 805 Highland Drive, Solana Beach, CA 92075 (US). GOLDMAN, Mark, E.; 4372 Corte de la Fonda, San Diego, CA 92130 (US). POOLEY, Charlotte, L., F.; 1037 Wilbur Avenue, San Diego, CA 92109 (US). WINN, David, T.; 4608 Huggins Way, San Diego, 92122 (US). EDWARDS, James, E.; 8723 Hesby Court, San Diego, CA 92129 (US). WEST, Sarah, J.; 4178 Decoro Street #92, San Diego, CA 92122 (US). TEGLEY, Christopher, M.; 13328 Caminito Ciera #10, San Diego, CA 92129 (US). ZHI, Lin; 7794 Roan Road, San Diego, CA 92129 (US). HAMANN, Lawrence, G.; Apartment #125, 4025 Porte la Paz, San Diego, CA 92122 (US). FARMER, Luc, J.; 3246-36 Caminito Eastbluff, La Jolla, CA 92037 (US). DAVIS, Robert, J.; 8018 Corte del Sol, Santee, CA 92071 (US).	
(22) International Filing Date: 13 December 1995 (13.12.95)			
(30) Priority Data:			
08/363,529	22 December 1994 (22.12.94)	US	
08/464,541	5 June 1995 (05.06.95)	US	
08/463,231	5 June 1995 (05.06.95)	US	
08/464,546	5 June 1995 (05.06.95)	US	
08/465,429	5 June 1995 (05.06.95)	US	
08/464,360	5 June 1995 (05.06.95)	US	
08/462,643	5 June 1995 (05.06.95)	US	
08/465,556	5 June 1995 (05.06.95)	US	
(71) Applicant: LIGAND PHARMACEUTICALS INCORPORATED [US/US]; 9393 Towne Centre Drive, San Diego, CA 92121 (US).		(74) Agents: JURGENSEN, Thomas, E. et al.; Ligand Pharmaceuticals Inc., 9393 Towne Centre Drive, San Diego, CA 92121 (US).	
		(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, LS, MW, SD, SZ, UG).	
		Published <i>Without international search report and to be republished upon receipt of that report.</i>	

(54) Title: **STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS**

(57) Abstract

Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.

[illegible]

wherein:

R^1 is a heteroaryl optionally substituted with a $C_1 - C_4$ alkyl, F, Cl, Br, NO_2 , CO_2H , CO_2R^2 , CHO, CN, CF_3 , CH_2OH or $COCH_3$, where R^2 is hydrogen, a $C_1 - C_4$ alkyl or perfluoroalkyl, aryl, heteroaryl or optionally substituted allyl, arylmethyl, alkynyl or alkenyl, and where said R^1 heteroaryl is attached to compounds of formulas I and X through a carbon or nitrogen atom;

R^3 is hydrogen, a $C_1 - C_4$ alkyl or perfluoroalkyl, hydroxymethyl, aryl, heteroaryl or optionally substituted allyl, arylmethyl, alkynyl or alkenyl;

R^4 through R^6 each independently are hydrogen, F, Cl, Br, I, NO_2 , CO_2H , CO_2R^2 , COR^2 , CN, CF_3 , CH_2OH , a $C_1 - C_4$ alkyl or perfluoroalkyl, OR^2 , SR^2 , $S(O)R^2$, SO_2R^2 , SO_3H , $S(NR^2R^7)R^2$, $S(O)(NR^2R^7)R^2$, NR^2R^7 , aryl, heteroaryl or optionally substituted allyl, arylmethyl, alkynyl or alkenyl, where R^2 has the definition given above, R^7 is hydrogen, a $C_1 - C_4$ alkyl or perfluoroalkyl, aryl, heteroaryl, optionally substituted allyl or arylmethyl, OR^8 or NHR^8 , where R^8 is hydrogen, a $C_1 - C_6$ alkyl or perfluoroalkyl, aryl, heteroaryl, optionally substituted allyl or arylmethyl, SO_2R^2 or $S(O)R^2$;

R^9 and R^{10} each independently are hydrogen, a $C_1 - C_6$ alkyl or perfluoroalkyl, aryl, heteroaryl or optionally substituted allyl, arylmethyl, alkynyl or alkenyl, or R^9 and R^{10} taken together can form a three- to seven-membered ring optionally substituted with hydrogen, F, OR^2 , or NR^2R^7 , where R^2 and R^7 have the definitions given above;

R^{11} through R^{15} each independently are hydrogen, F, Cl, Br, I, NO_2 , CO_2H , CO_2R^2 , COR^2 , CN, CF_3 , CH_2OH , a $C_1 - C_4$ alkyl or perfluoroalkyl, OR^2 , SR^2 , $S(O)R^2$, SO_2R^2 , SO_3H , $S(NR^2R^7)R^2$, $S(O)(NR^2R^7)R^2$, NR^2R^7 , aryl, heteroaryl or optionally substituted allyl, arylmethyl, alkynyl or alkenyl, where R^2 , R^7 and R^8 have the definitions given above;

W is O, NH, NR⁷, CH₂, CHOH, C=O, OC=O, O=CO, NR⁷C=O, NHC=O, O=CNR⁷, O=CNH, SC=O, O=CS, or CHOCOR⁷, where R⁷ has the definition given above, except that when W is NH, CH₂ or O in the compounds of formula III, then R¹¹ through R¹⁴ and R⁴ cannot all be hydrogen when R³, R⁹ and R¹⁰ are all CH₃, nor can they be a single F, Cl or Br substituent with the remaining substituents all being hydrogen when R³, R⁹ and R¹⁰ are all CH₃, and further except that when W is O or NH in the compounds of formula IV, then R⁵ through R⁶ and R¹¹ through R¹⁴ cannot all be hydrogen when R³, R⁹ and R¹⁰ are all CH₃;

X is CH₂, O, S or NR⁷, where R⁷ has the definition given above;

R¹⁶ is hydrogen, OH, OR¹⁷, SR¹⁷, NR²R⁷, optionally substituted allyl, arylmethyl, alkynyl, alkenyl, aryl, heteroaryl or C₁ - C₁₀ alkyl, where R¹⁷ is a C₁ - C₁₀ alkyl or perfluoroalkyl, or is an optionally substituted allyl, arylmethyl, aryl or heteroaryl, and where R² and R⁷ have the definitions given above;

R¹⁸ and R¹⁹ each independently are hydrogen, a C₁ - C₆ alkyl or perfluoroalkyl, aryl, heteroaryl or optionally substituted allyl, arylmethyl, alkynyl or alkenyl, or R¹⁸ and R¹⁹ taken together can form a three- to seven-membered ring optionally substituted with hydrogen, F, OR², or NR⁷R⁸, where R², R⁷ and R⁸ have the definitions given above;

R²⁰ is a C₁ - C₆ alkyl or an optionally substituted allyl, arylmethyl, alkenyl, aryl or heteroaryl;

R²¹ is hydrogen, a C₁ - C₄ alkyl or optionally substituted allyl, arylmethyl, aryl or heteroaryl;

R²² is hydrogen, a C₁ - C₄ alkyl, F, Cl, Br, I, OR², NR²R⁷ or SR², where R² and R⁷ have the definitions given above;

R^{23} is hydrogen, Cl, Br, OR^8 , NR^2R^7 , a $C_1 - C_4$ alkyl or perhaloalkyl, or is an optionally substituted allyl, arylmethyl, alkynyl, alkenyl, aryl or heteroaryl, where R^2 , R^7 and R^8 have the definitions given above;

R^{24} is hydrogen, F, Br, Cl, a $C_1 - C_4$ alkyl or perhaloalkyl, aryl, heteroaryl, CF_3 , CF_2OR^{25} , CH_2OR^{25} , or OR^{25} , where R^{25} is a $C_1 - C_4$ alkyl, except that R^{24} cannot be CH_3 when Z is O, R^{22} , R^{23} , R^{26} and R^{29} are all hydrogen and R^3 , R^{27} and R^{28} all are CH_3 ;

R^{26} is hydrogen, a $C_1 - C_4$ alkyl, F, Cl, Br, I, OR^2 , NR^2R^7 or SR^2 , where R^2 and R^7 have the definitions given above;

R^{27} and R^{28} each independently are hydrogen, a $C_1 - C_4$ alkyl or perfluoroalkyl, heteroaryl, optionally substituted allyl, arylmethyl, alkynyl or alkenyl, or an aryl optionally substituted with hydrogen, F, Cl, Br, OR^2 or NR^2R^7 , or R^{27} and R^{28} taken together can form a three- to seven-membered ring optionally substituted with hydrogen, F, Cl, Br, OR^2 or NR^2R^7 , where R^2 and R^7 have the definitions given above;

R^{29} is hydrogen, a $C_1 - C_6$ alkyl or an optionally substituted allyl, arylmethyl, aryl or heteroaryl;

R^{30} and R^{31} each independently are hydrogen, a $C_1 - C_6$ alkyl or an optionally substituted allyl, arylmethyl, aryl or heteroaryl, or R^{30} and R^{31} taken together can form a three- to seven-membered ring optionally substituted with hydrogen, F, Cl, OR^2 or NR^2R^7 , where R^2 and R^7 have the definitions given above;

R^{32} and R^{33} each independently are hydrogen, a $C_1 - C_4$ alkyl or an aryl optionally substituted with hydrogen, F, Cl, Br, OR^2 or NR^2R^7 , or R^{32} and R^{33} taken together can form a three- to seven-membered ring optionally substituted with hydrogen, F, Cl, Br, OR^2 or NR^2R^7 , where R^2 and R^7 have the definitions given above;

n is 0 or 1;

Y is O or S;

Z is O, S, NH, NR² or NCOR², where R² has the same definition given above;

- the wavy line in the compounds of formulas VII, XII, XIII and XVI represent an
- 5 olefin bond in either the *cis* or *trans* configuration; and
- the dotted lines in the structures depict optional double bonds, except that when there is a C₃ - C₄ double bond in the nitrogen bearing ring of compounds of formula II, then R¹¹ through R¹⁵ cannot all be hydrogen and R³, R⁹ and R¹⁰ cannot all be methyl, and further except when R²³ is an aryl, R²², R²⁴ and R²⁹ are all hydrogen, R³ is CH₃ and Z is NR²,
- 10 then R² cannot be a C₁ - C₄ alkyl.

2. A compound according to claim 1, wherein the compounds of formulae I through XVIII comprise steroid receptor modulator compounds.

- 15 3. A compound according to claim 2, wherein the compounds of formulae I, II, III, IV, X and XI comprise PR antagonists.

4. A compound according to claim 2, wherein the compounds of formulae V and VI comprise PR modulators.

20

5. A compound according to claim 2, wherein the compounds of formulae VII, VIII, XII, XIII, XIV, XV and XVI comprise PR agonists.

- 25 6. A compound according to claim 2, wherein the compounds of formulae IX, XVII and XVIII comprise AR modulators.

7. A compound according to claim 6, wherein the compounds of formulae IX and XVII comprise AR antagonists.

It is not clear whether R_2 or $NCOR_2$ where R_2 has the same definition given above.

na: 1000, gen IVX bna: 1000, IDX, IVX, and other to show some: sit in and view ad

long, narrow, dense forest to the east, north of the lake.

graphically, the results show that the location of the structure is of great importance.

11. The β -hydroxy acid is the starting material for the synthesis of compounds of formula II, where

cannot all be hydrogen and R_1, R_2 and R_3 cannot all be methyl, and further

²³ R = H and R' = CH₃; ²⁴ R = H and R' = CH₃; ²⁵ R = H and R' = CH₃; ²⁶ R = H and R' = CH₃; ²⁷ R = H and R' = CH₃; ²⁸ R = H and R' = CH₃; ²⁹ R = H and R' = CH₃; ³⁰ R = H and R' = CH₃; ³¹ R = H and R' = CH₃; ³² R = H and R' = CH₃; ³³ R = H and R' = CH₃; ³⁴ R = H and R' = CH₃; ³⁵ R = H and R' = CH₃; ³⁶ R = H and R' = CH₃; ³⁷ R = H and R' = CH₃; ³⁸ R = H and R' = CH₃; ³⁹ R = H and R' = CH₃; ⁴⁰ R = H and R' = CH₃; ⁴¹ R = H and R' = CH₃; ⁴² R = H and R' = CH₃; ⁴³ R = H and R' = CH₃; ⁴⁴ R = H and R' = CH₃; ⁴⁵ R = H and R' = CH₃; ⁴⁶ R = H and R' = CH₃; ⁴⁷ R = H and R' = CH₃; ⁴⁸ R = H and R' = CH₃; ⁴⁹ R = H and R' = CH₃; ⁵⁰ R = H and R' = CH₃; ⁵¹ R = H and R' = CH₃; ⁵² R = H and R' = CH₃; ⁵³ R = H and R' = CH₃; ⁵⁴ R = H and R' = CH₃; ⁵⁵ R = H and R' = CH₃; ⁵⁶ R = H and R' = CH₃; ⁵⁷ R = H and R' = CH₃; ⁵⁸ R = H and R' = CH₃; ⁵⁹ R = H and R' = CH₃; ⁶⁰ R = H and R' = CH₃; ⁶¹ R = H and R' = CH₃; ⁶² R = H and R' = CH₃; ⁶³ R = H and R' = CH₃; ⁶⁴ R = H and R' = CH₃; ⁶⁵ R = H and R' = CH₃; ⁶⁶ R = H and R' = CH₃; ⁶⁷ R = H and R' = CH₃; ⁶⁸ R = H and R' = CH₃; ⁶⁹ R = H and R' = CH₃; ⁷⁰ R = H and R' = CH₃; ⁷¹ R = H and R' = CH₃; ⁷² R = H and R' = CH₃; ⁷³ R = H and R' = CH₃; ⁷⁴ R = H and R' = CH₃; ⁷⁵ R = H and R' = CH₃; ⁷⁶ R = H and R' = CH₃; ⁷⁷ R = H and R' = CH₃; ⁷⁸ R = H and R' = CH₃; ⁷⁹ R = H and R' = CH₃; ⁸⁰ R = H and R' = CH₃; ⁸¹ R = H and R' = CH₃; ⁸² R = H and R' = CH₃; ⁸³ R = H and R' = CH₃; ⁸⁴ R = H and R' = CH₃; ⁸⁵ R = H and R' = CH₃; ⁸⁶ R = H and R' = CH₃; ⁸⁷ R = H and R' = CH₃; ⁸⁸ R = H and R' = CH₃; ⁸⁹ R = H and R' = CH₃; ⁹⁰ R = H and R' = CH₃; ⁹¹ R = H and R' = CH₃; ⁹² R = H and R' = CH₃; ⁹³ R = H and R' = CH₃; ⁹⁴ R = H and R' = CH₃; ⁹⁵ R = H and R' = CH₃; ⁹⁶ R = H and R' = CH₃; ⁹⁷ R = H and R' = CH₃; ⁹⁸ R = H and R' = CH₃; ⁹⁹ R = H and R' = CH₃; ¹⁰⁰ R = H and R' = CH₃.

When R cannot be a C alkyl

[illegible]

through X-III esterase steroid receptor modulator compounds

If I returned to shore once at night, I could not understand him.

12345678910111213141516171819202122232425262728293031323334353637383940414243444546474849505152535455565758596061626364656667686970717273747576777879808182838485868788899091929394959697989910010110210310410510610710810911011111211311411511611711811912012112212312412512612712812913013113213313413513613713813914014114214314414514614714814915015115215315415515615715815916016116216316416516616716816917017117217317417517617717817918018118218318418518618718818919019119219319419519619719819920020120220320420520620720820921021121221321421521621721821922022122222322422522622722822923023123223323423523623723823924024124224324424524624724824925025125225325425525625725825926026126226326426526626726826927027127227327427527627727827928028128228328428528628728828929029129229329429529629729829930030130230330430530630730830931031131231331431531631731831932032132232332432532632732832933033133233333433533633733833934034134234334434534634734834935035135235335435535635735835936036136236336436536636736836937037137237337437537637737837938038138238338438538638738838939039139239339439539639739839940040140240340440540640740840941041141241341441541641741841942042142242342442542642742842943043143243343443543643743843944044144244344444544644744844945045145245345445545645745845946046146246346446546646746846947047147247347447547647747847948048148248348448548648748848949049149249349449549649749849950050150250350450550650750850951051151251351451551651751851952052152252352452552652752852953053153253353453553653753853954054154254354454554654754854955055155255355455555655755855956056156256356456556656756856957057157257357457557657757857958058158258358458558658758858959059159259359459559659759859960060160260360460560660760860961061161261361461561661761861962062162262362462562662762862963063163263363463563663763863964064164264364464564664764864965065165265365465565665765865966066166266366466566666766866967067167267367467567667767867968068168268368468568668768868969069169269369469569669769869970070170270370470570670770870971071171271371471571671771871972072172272372472572672772872973073173273373473573673773873974074174274374474574674774874975075175275375475575675775875976076176276376476576676776876977077177277377477577677777877978078178278378478578678778878979079179279379479579679779879980080180280380480580680780880981081181281381481581681781881982082182282382482582682782882983083183283383483583683783883984084184284384484584684784884985085185285385485585685785885986086186286386486586686786886987087187287387487587687787887988088188288388488588688788888989089189289389489589689789889990090190290390490590690790890991091191291391491591691791891992092192292392492592692792892993093193293393493593693793893994094194294394494594694794894995095195295395495595695795895996096196296396496596696796896997097197297397497597697797897998098198298398498598698798898999099199299399499599699799899910001001100210031004100510061007100810091010101110121013101410151016101710181019102010211022102310241025102610271028102910301031103210331034103510361037103810391040104110421043104410451046104710481049105010511052105310541055105610571058105910601061106210631064106510661067106810691070107110721073107410751076107710781079108010811082108310841085108610871088108910901091109210931094109510961097109810991100110111021103110411051106110711081109111011111112111311141115111611171118111911201121112211231124112511261127112811291130113111321133113411351136113711381139114011411142114311441145114611471148114911501151115211531154115511561157115811591160116111621163116411651166116711681169117011711172117311741175117611771178117911801181118211831184118511861187118811891190119111921193119411951196119711981199120012011202120312041205120612071208120912101211121212131214121512161217121812191220122112221223122412251226122712281229123012311232123312341235123612371238123912401241124212431244124512461247124812491250125112521253125412551256125712581259126012611262126312641265126612671268126912701271127212731274127512761277127812791280128112821283128412851286128712881289129012911292129312941295129612971298129913001

Is Y related to the number of members X in a religious household A ?

Conclusion IV

ITV column to show correct cell identity. I made an antibody haemagglutination assay within the correct cell identity.

minutes 21 minutes 17X 18X 19X 20X 21X

XI admitted to abductees all nine of 5 units or military headquarters. A

crystalloborn 84, eritropo IV/X bna IV/X

A compound according to claim 3 wherein the compound is of formula IX

Handwritten: 24 November 1971

**SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO
DIVISIÓN DE NUEVAS CREACIONES**

2020
Bogotá, D.C.,

Abogado
✓ **CARLOS R. OLARTE**

ASUNTO	Radicación	05-96777
	Trámite	002
	Evento	001
	Actuación	430
	Oficio	3506
	Folios	10

Patente de Invención ☒ Patente de Modelo de Utilidad ☐

Vía Nacional ☐

Vía PCT (fase nacional) ☒ Cap. I ☐ Cap. II ☒

No. Sol. Internacional PCT/IB2004/000836
Fecha de Presentación Internal. 15-03-2004

Como resultado del examen de fondo, realizado con fundamento en el artículo 45 de la Decisión 486 de la Comisión de la Comunidad Andina, se le comunica:

1. Documentos estudiados

Descripción: Folios: 173 a 377 (como se radicó inicialmente)

Reivindicaciones: Folios 378 a 389 (como se radicó inicialmente)

Prioridad: Folio: 1
Fecha: 28-03-2003; país y número: US60/458.274.

2. Objeto de la Invención

Titulo de la invención: "1,2,4-SUSTITUYENTE 1,2,3,4-TETRAHIDRO Y 1,2-DIHIDRO-QUINOLINA Y DERIVADOS E 1,2,3,4-TETRAHIDROQUINOXALINA COMO INHIBIDORES CETP PARA EL TRATAMIENTO DE ATROSCLEROSIS Y OBESIDAD."

Problema Técnico Planteado: La necesidad de incrementar los niveles de lipoproteína de alta densidad (HDL) del colesterol en plasma y reducir los niveles de lipoproteína de baja densidad (LDL) con el fin de tratar enfermedades cardiovasculares y aterosclerosis.

Solución: Derivados de quinolina y quinoxalina y composiciones que los contienen.

IPC: A61K 31/47; A61P 3/04; A61K 31/4709.

3. De la solicitud de Patente

a. Reivindicaciones (artículo 30 D 486)

La reivindicación 1 carece de concisión debido a que presenta un número indeterminado de compuestos con variaciones estructurales significativas entre si por lo que es imposible determinar si todos ellos poseen la actividad terapéutica que el solicitante les atribuye lo cual no puede establecerse debido a que la descripción carece de información que soporte dicha actividad.

Las reivindicaciones 8, 10, 11, 14 y 15 reclaman profármacos de los compuestos, estos profármacos carecen de soporte alguno en la descripción que le permita al experto en la materia obtenerlos ya que ni siquiera se establece la estructura de los mismos

Por lo anterior las reivindicaciones mencionadas no cumplen con el requisito de definición, claridad, concisión o sustento por la descripción de acuerdo al art. 30 de la Decisión 486 y/o art. 22 Tratado PCT.

4. Unidad de invención (artículo 25 D 486)

La reivindicación 14 reclama un kit para conseguir efecto terapéutico en un mamífero que comprende un envase y dos agentes terapéuticos. Esta reclamación corresponde a un concepto inventivo diferente al del resto de la solicitud ya que requiere el estudio del envase, su conformación, y el establecimiento de la existencia en conjunto del envase con la sustancias.

5. Excepción a la patentabilidad (artículo 20 D486 literal d)

La reivindicación 9 reclama un procedimiento para tratar aterosclerosis. Esta reivindicación no es patentable.

6. Determinación del Estado de la Técnica

La fecha que se ha tenido en cuenta para determinar el Estado de la Técnica es:

Fecha de presentación de la solicitud prioritaria 28-03-2003

Teniendo en cuenta la fecha indicada se realizó la búsqueda en el estado de la técnica de documentos relacionados con la solicitud encontrándose los siguientes documentos más relevantes:


Nº	Documento	Título	Fecha de publicación*
D1	WO96/19458	STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS	27-06-1996

7. Análisis de Patentabilidad (Art 14 D486)

Novedad (Art 16 D486)

1) Respecto a la solicitud en estudio:

La reivindicación 1 reclama compuestos de la fórmula (I):




Formula I

La reivindicación 10 reclama una composición farmacéutica que comprende una cantidad terapéuticamente eficaz de un compuesto de las reivindicaciones 1 a 8.


La reivindicación 11 reclama una combinación farmacéutica que comprende un compuesto de la fórmula (I), y un segundo compuesto activo.

La reivindicación 15 reclama un compuesto de la fórmula III



2) Respecto al estado de la Técnica:

D1 divulga derivados de la fórmula:



- Cuando en D1
- Y= oxígeno (pág 343)
- Z= O, S ó NH (pág 343)
- R³= alquil, alquinil, alquenil, arilmetil. (pág. 340)
- R²²⁻²⁷ = H; (pág 341-342)
- R²⁸= alquil C1-4, alquenil o alquinil. (pág 342)
- R²⁹= alquil C1-6, alil.

Se evidencia que los compuestos reclamados en la presente solicitud ya se habian divulgado en D1. En consecuencia las reivindicaciones 1-8 y 10-13 no son nuevas.

8. Conclusión

Los requisitos de Patentabilidad de la presente Solicitud se encuentran afectados así:

Nº	Documento	Reivindicaciones afectadas	Requisito que afecta
D1	WO 96/19458	1-8 y 10-13	Novedad

En cumplimiento del artículo 45 de la Decisión 486 de la Comisión de la Comunidad Andina, se le indica que debe dar respuesta dentro del término de sesenta días contados a partir de la fecha de notificación de la presente comunicación. En caso de no dar respuesta al presente requerimiento, o si a pesar de la respuesta subsistieran los impedimentos para la concesión, se denegará la patente.